Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CEO Backer Marianne De sold 72,995 shares of the business's stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total value of $690,532.70. Following the sale, the chief executive officer now directly owns 678,457 shares in the company, valued at approximately $6,418,203.22. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Vir Biotechnology Trading Down 2.3 %
Vir Biotechnology stock opened at $9.47 on Friday. The stock has a 50-day moving average price of $10.20 and a 200 day moving average price of $9.65. Vir Biotechnology, Inc. has a 52 week low of $7.72 and a 52 week high of $27.48.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.28. The company had revenue of $16.80 million for the quarter, compared to analysts' expectations of $11.18 million. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The firm's revenue for the quarter was down 66.0% compared to the same quarter last year. During the same period last year, the company earned ($0.76) EPS. As a group, equities research analysts expect that Vir Biotechnology, Inc. will post -4.04 earnings per share for the current year.
Institutional Investors Weigh In On Vir Biotechnology
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
Several hedge funds have recently made changes to their positions in VIR. Quadrant Capital Group LLC increased its stake in Vir Biotechnology by 274.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,970 shares of the company's stock valued at $30,000 after purchasing an additional 2,177 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Vir Biotechnology by 96.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,448 shares of the company's stock valued at $32,000 after buying an additional 1,692 shares during the period. Signaturefd LLC grew its holdings in Vir Biotechnology by 258.5% in the 4th quarter. Signaturefd LLC now owns 3,327 shares of the company's stock valued at $33,000 after buying an additional 2,399 shares during the period. Fifth Third Bancorp increased its stake in shares of Vir Biotechnology by 69.3% during the 3rd quarter. Fifth Third Bancorp now owns 3,941 shares of the company's stock valued at $37,000 after acquiring an additional 1,613 shares during the last quarter. Finally, Captrust Financial Advisors lifted its holdings in shares of Vir Biotechnology by 1,270.7% during the 2nd quarter. Captrust Financial Advisors now owns 1,823 shares of the company's stock worth $46,000 after acquiring an additional 1,690 shares during the period. Institutional investors and hedge funds own 65.32% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have commented on VIR shares. HC Wainwright reiterated a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, March 15th. JPMorgan Chase & Co. lifted their price target on Vir Biotechnology from $9.00 to $10.00 and gave the stock a "neutral" rating in a research note on Friday, February 23rd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Vir Biotechnology currently has a consensus rating of "Moderate Buy" and a consensus target price of $34.38.
Read Our Latest Research Report on Vir Biotechnology
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
